LoadingLoadingLoadingNet selling: insiders sold $6.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
Susquehanna
$68.2M
added
Balyasny
$42.4M
bought
Sells/Trims (1)
Squarepoint
$26.3M
trimmed
No tracked top-trader positions in MDGL as of Oct 24, 05:27 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Earnings per share
-$2.23 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
-$1.38 to -$0.56
Revenue expected
17 analysts
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | -$1.99 / -$2.23Yahoo Finance | +10.76% beat | $364.3M No estimate | Unavailable |
| Mar 31, 2026 | May 6, 2026 | -$1.38 / -$4.14Yahoo Finance | +66.70% beat | $311.3M No estimate | Unavailable |
| Dec 31, 2025 | Feb 19, 2026 | -$2.57 / -$0.88Yahoo Finance | -$1.69 miss | $321.1M No estimate | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | -$4.96 / -$1.99Yahoo Finance | -148.77% miss | $287.3M No estimate | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | -$1.90 / -$3.53Alpha Vantage | +46.18% beat | $212.8M No estimate | Unavailable |
| Mar 31, 2025 | May 1, 2025 | -$3.32 / -$3.79Alpha Vantage | +12.40% beat | $137.3M No estimate | Unavailable |
| Dec 31, 2024 | Feb 26, 2025 | -$2.71 / -$4.12Alpha Vantage | +34.30% beat | $103.3M No estimate | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | -$4.92 / -$6.91Alpha Vantage | +28.80% beat | $62.2M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $287.3M | $321.1M | $311.3M | $364.3M |
| Cost of what it sold | $18.1M | $24.4M | $26.8M | $40.0M |
| Gross profit | $269.1M | $296.6M | $284.5M | $324.2M |
| What it spent | ||||
| Research and development | $174.0M | $116.3M | $108.7M | $91.2M |
| Sales and admin | $209.1M | $209.1M | $268.5M | $289.4M |
| Other operating costs | — | $30.9M | — | — |
| Total operating expenses | $383.1M | $356.2M | $377.2M | $380.6M |
| What was left | ||||
| Operating profit | -$114.0M | -$59.6M | -$92.7M | -$56.3M |
| Interest on debt | $7.5M | $8.3M | $7.8M | $7.9M |
| Profit before tax | -$114.2M | -$58.6M | -$94.4M | -$57.9M |
| Net profit | -$114.2M | -$58.6M | -$94.4M | -$57.9M |
| EBITDA | -$106.4M | -$49.9M | -$86.2M | -$49.6M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Madrigal Grants Equity Awards to 26 New Employees
Leans bullishOct 21Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, News, Quote & History
NeutralOct 21Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
NeutralOct 20Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
NeutralOct 20Lobbying Update: $350,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed
Leans bearishOct 20BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating
Leans bearishOct 19UBS raises target to USD 735.00 for Madrigal Pharmaceuticals stock
BullishOct 17Did Genetic Response Data Just Shift Madrigal Pharmaceuticals (MDGL) Investment Narrative?
Leans bullishOct 17
